GWLL — Goldenwell Biotech Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Goldenwell Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	0	0.016	0.048	0.002
Cost of Revenue
Gross Profit	0	0	0.008	0.025	0.001
Selling / General / Administrative Expenses
Total Operating Expenses	0.003	0.006	0.134	1.03	0.119
Operating Profit	-0.002	-0.006	-0.118	-0.985	-0.117
Other Net Non Operating Costs
Net Income Before Taxes	-0.002	-0.006	-0.117	-0.985	-0.117
Provision for Income Taxes
Net Income After Taxes	-0.002	-0.006	-0.117	-0.985	-0.117
Net Income Before Extraordinary Items
Net Income	-0.002	-0.006	-0.117	-0.985	-0.117
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-0.002	-0.006	-0.117	-0.985	-0.117
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0	-0	-0.001	-0.01	-0.001
Dividends per Share